Abstract
FK506 binding protein 51 (FKBP51) is an immunophilin physiologically expressed in lymphocytes. Very recently, aberrant expression of this protein was found in melanoma; FKBP51 expression correlates with melanoma aggressiveness and is maximal in metastatic lesions. FKBP51 promotes NF-κB activation and is involved in the resistance to genotoxic agents, including anthracyclines and ionizing radiation. FKBP51 is a cochaperone with peptidyl-prolyl isomerase activity that regulates several biological processes through protein-protein interaction. There is increasing evidence that FKBP51 hyperexpression is associated with cancer and this protein has a relevant role in sustaining cell growth, malignancy, and resistance to therapy. There is also evidence that FKBP ligands are potent anticancer agents, in addition to their immunosuppressant activity. In particular, rapamycin and its analogs have shown antitumor activity across a variety of human cancers in clinical trials. Although, classically, rapamycin actions are ascribed to inhibition of mTOR, recent studies indicate FKBP51 is also an important molecular determinant of the drugs anticancer activity. The aim of this article is to review the functions of FKBP51, especially in view of the recent findings that this protein is a potential oncogene when deregulated and a candidate target for signaling therapies against cancer.
Keywords: FKBP51, cancer, apoptosis, NF-κB, rapamycin, FK506 binding protein, immunophilin, physiologically expressed, lymphocytes, melanoma aggressiveness
Current Medicinal Chemistry
Title: The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer
Volume: 18 Issue: 35
Author(s): S. Romano, A. Sorrentino, A. L. Di Pace, G. Nappo, C. Mercogliano and M. F. Romano
Affiliation:
Keywords: FKBP51, cancer, apoptosis, NF-κB, rapamycin, FK506 binding protein, immunophilin, physiologically expressed, lymphocytes, melanoma aggressiveness
Abstract: FK506 binding protein 51 (FKBP51) is an immunophilin physiologically expressed in lymphocytes. Very recently, aberrant expression of this protein was found in melanoma; FKBP51 expression correlates with melanoma aggressiveness and is maximal in metastatic lesions. FKBP51 promotes NF-κB activation and is involved in the resistance to genotoxic agents, including anthracyclines and ionizing radiation. FKBP51 is a cochaperone with peptidyl-prolyl isomerase activity that regulates several biological processes through protein-protein interaction. There is increasing evidence that FKBP51 hyperexpression is associated with cancer and this protein has a relevant role in sustaining cell growth, malignancy, and resistance to therapy. There is also evidence that FKBP ligands are potent anticancer agents, in addition to their immunosuppressant activity. In particular, rapamycin and its analogs have shown antitumor activity across a variety of human cancers in clinical trials. Although, classically, rapamycin actions are ascribed to inhibition of mTOR, recent studies indicate FKBP51 is also an important molecular determinant of the drugs anticancer activity. The aim of this article is to review the functions of FKBP51, especially in view of the recent findings that this protein is a potential oncogene when deregulated and a candidate target for signaling therapies against cancer.
Export Options
About this article
Cite this article as:
Romano S., Sorrentino A., L. Di Pace A., Nappo G., Mercogliano C. and F. Romano M., The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer, Current Medicinal Chemistry 2011; 18 (35) . https://dx.doi.org/10.2174/092986711798194333
DOI https://dx.doi.org/10.2174/092986711798194333 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification and Characterization of BRCA1 and BRCA2 Founder Mutations
Current Women`s Health Reviews Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Current Medicinal Chemistry ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors
Medicinal Chemistry Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Identification of Novel Antagonists for Rab38 Protein by Homology Modeling and Virtual Screening
Combinatorial Chemistry & High Throughput Screening Do Insecticides have Adverse Effects on Reproduction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology Contemporary Progress in the Synthetic Strategies of Imidazole and its Biological Activities
Current Organic Synthesis Viral Origins of Human Cancer
Current Medicinal Chemistry Anticancer Studies of Leucovorin against Methotrexate Induced Genotoxicity in Swiss Albino Mice
Letters in Drug Design & Discovery Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry GqPCR-mediated Signalling in the Spotlight: From Visualization Towards Dissection and Quantification
Current Pharmaceutical Biotechnology Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design